# Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

> **NCT06585514** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)

## Interventions

- **DRUG:** CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT06585514
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585514, "Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06585514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*